Castle Biosciences says prospective study shows low-risk DecisionDx-Melanoma results link to 4.4% SLN positivity, 99.6% five-year RFS without SLNB

By Public Technologies
  • Castle Biosciences will present late-breaking EADV 2026 data on DecisionDx-Melanoma on Oct. 1 in Vienna.
  • The prospective, multicenter study supports using the test to help some melanoma patients skip sentinel lymph node biopsy.
  • Outcomes also back using the assay to flag early-stage patients who may need closer post-surgical surveillance.
  • Separate EADV ePoster data indicate the test can clarify recurrence risk when biopsy-based staging is uncertain due to transected tumors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA60742) on September 30, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk